Original Article

You have full text access to this OnlineOpen article

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure†

  1. Jean-Jacques Body1,*,
  2. Allan Lipton2,
  3. Julie Gralow3,
  4. Guenther G Steger4,
  5. Guozhi Gao5,
  6. Howard Yeh6,
  7. Karim Fizazi7

Article first published online: 18 MAR 2010

DOI: 10.1359/jbmr.090810

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 3, pages 440–446, March 2010

Additional Information

How to Cite

Body, J.-J., Lipton, A., Gralow, J., Steger, G. G., Gao, G., Yeh, H. and Fizazi, K. (2010), Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res, 25: 440–446. doi: 10.1359/jbmr.090810

Author Information

  1. 1

    CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium

  2. 2

    Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

  3. 3

    University of Washington Cancer Care Alliance, Seattle, Washington

  4. 4

    Medical University of Vienna, Vienna, Austria

  5. 5

    Amgen, Inc., San Francisco, California

  6. 6

    Amgen, Inc., Thousand Oaks, California

  7. 7

    Department of Medicine, Institut Gustave Roussy and University of Paris XI, Villejuif, France

*CHU Brugmann (Université Libre de Bruxelles), 4 Place Van Gehuchten, 1020 Brussels, Belgium.

  1. †

    Prior abstract presentation: Some of the information presented in this article was reported at the American Society of Clinical Oncology Congress, Chicago, IL, USA, May 30–June 3, 2008 and at the European Society for Medical Oncology Congress, Stockholm, Sweden, September 12–16, 2008.

Publication History

  1. Issue published online: 18 MAR 2010
  2. Article first published online: 18 MAR 2010
  3. Accepted manuscript online: 27 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 30 JUL 2009
  5. Manuscript Revised: 21 MAY 2009
  6. Manuscript Received: 7 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (154K)

References

  • 1
    Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588–1594.
    Direct Link:
  • 2
    Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998; 77: 336–340.
  • 3
    Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19: 420–432.
  • 4
    Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613–2621.
    Direct Link:
  • 5
    Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 36–43.
    Direct Link:
  • 6
    Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–882.
  • 7
    Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188: 997–1001.
  • 8
    Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000; 157: 435–448.
  • 9
    Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–176.
  • 10
    Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059–1066.
    Direct Link:
  • 11
    Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221–1228.
  • 12
    Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875–4882.
  • 13
    Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59–69.
  • 14
    Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925–4935.
  • 15
    Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20: 850–856.
  • 16
    Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25: 4431–4437.
  • 17
    Fizazi K, Lipton A, Mariette X, et al. A randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasm after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564–1571.
  • 18
    Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14: 6690–6696.
  • 19
    Morony S, Warmington K, Adamu S, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005; 146: 3235–3243.
  • 20
    Tometsko M, Roudier M, Canon J, et al. RANKL inhibition causes a greater suppression of tumor-induced osteoclastogenesis than zoledronate treatment in vivo and RANKL rescues osteoclasts from zoledronate killing in vitro [Abstract M076 and Poster]. Am Soc Bone Miner Res 2006; 21: S346.
  • 21
    Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008; 180: 1154–1160.
  • 22
    Fizazi K, Beuzeboc P, Lumbroso J, et al. A prospective phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009; 27: 2429–2435.
  • 23
    Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357: 336–341.
View Full Article (HTML) Get PDF (154K)